Long-term corticosteroid treatment delays respiratory decline and heart disease in boys with Duchenne muscular dystrophy (Âé¶¹Éç) regardless of daily or…
Steve Bryson, PhD
Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. .
Articles by Steve Bryson, PhD
The U.S. Food and Drug Administration (FDA) has conditionally approved NS Pharma‘s…
Hansa Biopharma has granted an exclusive worldwide license to Sarepta Therapeutics…
Orsini Pharmaceutical Services is now providing Sarepta Therapeutics’ newly approved…
Duchenne UK is partnering with Catabasis Pharmaceuticals to provide financial support for a Phase 2…